111 Bundle
Who Really Owns 111 Company?
Understanding the ownership structure of a company is paramount for investors and analysts alike. For 111 Company (NASDAQ: YI), a leader in China's tech-enabled healthcare sector, knowing who holds the reins is crucial. This exploration unveils the evolution of 111 Company ownership, from its founding roots to its current public status, offering insights into its strategic direction and financial health.
111 Company's journey from a private startup, founded by Dr. Gang Yu and Mr. Junling Liu, to a publicly traded entity on the NASDAQ in 2018 is a fascinating case study in business ownership. This analysis will examine the key players influencing 111 Company, including the founders, early investors, and the impact of its IPO. For a deeper dive into the company's strategic position, consider exploring the 111 SWOT Analysis to understand its internal strengths and weaknesses.
Who Founded 111?
The story of 111 Company Ownership begins with its co-founders, Dr. Gang Yu and Mr. Junling Liu, who launched the company in 2010. Their initial venture, 1 Drugstore, marked a pioneering step in China's online pharmacy sector. While the exact initial equity split isn't publicly detailed, the founders strategically positioned themselves to retain significant control.
Upon the completion of the IPO, the founders, Dr. Gang Yu and Mr. Junling Liu, beneficially owned all of the issued and outstanding Class B ordinary shares. These Class B shares carried substantial voting power, with each share entitled to fifteen votes. This structure allowed the founders to maintain a firm grip on the company's direction.
As of September 2022, Dr. Gang Yu and Mr. Junling Liu, through their respective entities, held approximately 44.0% of the total outstanding share capital and about 92.0% of the aggregate voting power. This ownership structure highlights the founders' continued influence and control over the company, shaping its strategic decisions and long-term vision.
Early Ownership and Control
The early ownership structure of 111 Company reflects a strategic approach to maintain founder control and navigate regulatory landscapes. The founders utilized a variable interest entity (VIE) structure, common among Chinese companies listed overseas. This structure allowed them to manage foreign ownership restrictions while retaining significant influence over key operating entities.
- Guangdong Yihao Pharmacy Co., Ltd., a key VIE, was owned 50% by Mr. Yue Xuan, a family member of Dr. Gang Yu, and 50% by Ms. Jing Liu, a family member of Mr. Junling Liu.
- This arrangement further solidified the founders' control and vision for the company's early development.
- Understanding the 111 Company owner and its ownership structure is crucial for investors and stakeholders.
- For more insights, you might find the Competitors Landscape of 111 helpful.
111 SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has 111’s Ownership Changed Over Time?
The journey of 111 Company ownership began on September 12, 2018, when it went public on the Nasdaq Global Market under the symbol 'YI'. The initial public offering (IPO) saw 9.3 million American depositary shares (ADSs) offered at $14.00 each, raising approximately $100 million. At the time of the IPO, the total market capitalization was around $1.2 billion. However, by June 2025, the market capitalization had decreased to approximately $69.33 million USD, reflecting changes in the company's valuation and investor sentiment. This evolution highlights the dynamic nature of 111 Company ownership and its sensitivity to market conditions.
The ownership structure of 111 Company includes a mix of founders, institutional investors, and retail investors. As of May 23, 2025, institutional investors held 1.78% of the shares, while retail investors held 98.22%. The founders, Dr. Gang Yu and Mr. Junling Liu, retain significant influence through their Class B ordinary shares, which provide fifteen votes per share compared to one vote per Class A ordinary share. In September 2024, the co-founders, who beneficially owned 42.7% of the total issued share capital at that time, began purchasing additional company shares from their personal funds on the open market, indicating their continued confidence in the company. This signals a commitment to the company's future, despite the fluctuations in market capitalization.
| Key Event | Date | Impact on Ownership |
|---|---|---|
| Initial Public Offering (IPO) | September 12, 2018 | Company went public; founders, institutional, and retail investors gained ownership. |
| Co-founders' Share Purchases | September 2024 | Co-founders increased their stake, demonstrating confidence. |
| Withdrawal of Privatization Proposals | February 2024 | Company remained publicly traded. |
The major institutional shareholders as of May 23, 2025, include Renaissance Technologies Llc, Connor, Clark & Lunn Investment Management Ltd., Deuterium Capital Management, LLC, Morgan Stanley, and UBS Group AG. Harbourvest Partners LLC is the largest individual institutional shareholder, holding 903,117.00 shares, which represents 0.52% of the company. For more insights into the company's operations, you can explore the Revenue Streams & Business Model of 111.
Ownership Dynamics of 111 Company
The ownership of 111 Company involves founders, institutional, and retail investors.
- Founders hold significant influence.
- Institutional investors hold a small percentage.
- Retail investors hold the majority of shares.
- Market capitalization has decreased since the IPO.
111 PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on 111’s Board?
The current board of directors of 111, Inc. significantly influences the company's governance. The voting structure, however, heavily favors the founders. Shareholders can remove directors through ordinary resolution, but the dual-class share structure concentrates power.
The company's articles of association post-offering do not include cumulative voting. This means shareholders do not have more protections or rights in this area compared to shareholders of a Delaware corporation. The substantial voting power held by the founders implies their strong influence over board appointments and strategic directions. There have been no recent public reports of proxy battles or activist investor campaigns that have significantly challenged this concentrated voting power.
| Feature | Details | Impact |
|---|---|---|
| Voting Structure | Dual-class shares: Class A (1 vote), Class B (15 votes) | Concentrated control with founders. |
| Class B Ownership | Beneficially owned by co-founders Dr. Gang Yu and Mr. Junling Liu | Maintains significant influence over company decisions. |
| Voting Power (Sept 2022) | Founders held approximately 92.0% of the aggregate voting power | Founders retain outsized control despite institutional and retail ownership. |
The dual-class share structure of 111 Company ownership grants substantial control to the founders. This arrangement is a key consideration when assessing the company's governance and the influence of its leadership. For more insights into the company's strategic direction, consider the Target Market of 111.
Key Takeaways on 111 Company Ownership
The founders of 111 Company, Dr. Gang Yu and Mr. Junling Liu, maintain significant control due to their ownership of Class B shares.
- Dual-class share structure concentrates voting power.
- Founders' voting power was approximately 92.0% as of September 2022.
- Shareholders can remove directors by ordinary resolution.
- No cumulative voting is provided for.
111 Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped 111’s Ownership Landscape?
In the past few years, several developments have reshaped the ownership landscape of 111, Inc. In September 2024, a noteworthy move occurred as co-founders Dr. Gang Yu and Mr. Junling Liu, who held a collective stake of 42.7% of the company's issued share capital, initiated open market purchases of company shares using their personal funds. This action underscored their confidence in the company's intrinsic value. This occurred alongside the company reporting operational profitability for the second consecutive quarter in Q2 2024.
Financially, 111, Inc. achieved its first-ever annual operating profit and positive operating cash flow for the fiscal year ended December 31, 2024. Despite a challenging macroeconomic environment, net revenues were RMB14.4 billion (US$2.0 billion) for the full year 2024, a decrease of 3.7% from the previous year. However, operating expenses decreased by 31% year-over-year in 2024, reaching 5.7% of revenues, down from 8% in 2023, demonstrating improved operational efficiency. The company's net loss attributable to ordinary shareholders for 2024 significantly improved to RMB20.8 million (US$2.8 million), a 94.1% improvement from RMB353.4 million in 2023.
In February 2024, the consortium led by the co-founders withdrew their proposals to take the company private, signaling a continued commitment to its current ownership structure and public market presence. This decision reinforces that 111, Inc. will remain a publicly traded entity. The company is focused on expanding partnerships and leveraging AI and data analytics for growth. The company plans to add 15 more fulfillment centers in 2025 to bolster supply chain capabilities.
| Key Financial Data | 2024 | 2023 |
|---|---|---|
| Net Revenues (RMB) | 14.4 Billion | 14.9 Billion |
| Operating Expenses as % of Revenue | 5.7% | 8% |
| Net Loss Attributable to Ordinary Shareholders (RMB) | 20.8 Million | 353.4 Million |
111 Company Ownership
The co-founders, Dr. Gang Yu and Mr. Junling Liu, own a significant portion of the company. Their open market purchases of shares in 2024 show confidence in the company. Understanding 111 Company owner is key to understanding the company's direction.
Financial Performance
111 Company achieved its first annual operating profit in 2024. Despite a revenue decrease, operating expenses were significantly reduced. Net losses improved dramatically, showing operational improvements.
Strategic Direction
The company is focused on expanding partnerships and leveraging AI. Plans include adding more fulfillment centers to bolster supply chain capabilities. The company remains publicly traded.
Industry Trends
The Chinese healthcare sector is undergoing reforms. 111, Inc. plans to expand partnerships with pharmaceutical companies. The shift of drug sales to retail pharmacies is expected to accelerate.
111 Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of 111 Company?
- What is Competitive Landscape of 111 Company?
- What is Growth Strategy and Future Prospects of 111 Company?
- How Does 111 Company Work?
- What is Sales and Marketing Strategy of 111 Company?
- What is Brief History of 111 Company?
- What is Customer Demographics and Target Market of 111 Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.